+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Colony Stimulating Factor"

Neutropenia Biologic Drug Treatment Global Market Report 2024 - Product Thumbnail Image

Neutropenia Biologic Drug Treatment Global Market Report 2024

  • Report
  • February 2024
  • 250 Pages
  • Global
From
From
Endometriosis - Pipeline Insight, 2024 - Product Thumbnail Image

Endometriosis - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 80 Pages
  • Global
From
Graft versus host disease - Pipeline Insight, 2024 - Product Thumbnail Image

Graft versus host disease - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 220 Pages
  • Global
From
Neutropenia - Pipeline Insight, 2024 - Product Thumbnail Image

Neutropenia - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
From
From
JAK inhibitors - Competitive Landscape, 2023 - Product Thumbnail Image

JAK inhibitors - Competitive Landscape, 2023

  • Report
  • April 2023
  • 180 Pages
  • Global
From
From
  • 19 Results (Page 1 of 1)
Loading Indicator

Colony Stimulating Factor (CSF) is a type of drug used to treat immune disorders. It is a type of cytokine, a protein that helps regulate the immune system. CSF drugs are used to treat a variety of conditions, including neutropenia, anemia, and certain types of cancer. They can also be used to reduce the risk of infection in patients with weakened immune systems. CSF drugs work by stimulating the production of white blood cells, which help fight infection. CSF drugs are typically administered intravenously or subcutaneously. Common side effects include fever, chills, nausea, and headache. In some cases, CSF drugs can cause allergic reactions or anaphylaxis. The CSF market is a growing segment of the immune disorders drugs market. It is expected to continue to grow as more treatments become available and as the demand for immune-related treatments increases. Some companies in the CSF market include Amgen, Biogen, Celgene, and Novartis. Show Less Read more